

## **DERMANEX CREAM**

**For the use only of a Registered Medical Practitioner only**

Abbreviated Prescribing information for Dermanex cream (Mometasone furoate 0.1%) [Please refer the complete prescribing information available at [www.torrentpharma.com](http://www.torrentpharma.com)]

**PHARMACOLOGICAL PROPERTIES:** Mometasone furoate is a corticosteroid used topically for its glucocorticoid activity in the treatment of various skin disorders. Mometasone furoate exhibits marked anti-inflammatory activity and marked anti-psoriatic activity.

**INDICATION:** Dermanex cream is indicated for the treatment of inflammatory and pruritic manifestations of psoriasis (excluding widespread plaque psoriasis) and atopic dermatitis.

**DOSAGE AND ADMINISTRATION:** Adults, including elderly patients and Children: A thin film of Dermanex cream should be applied to the affected areas of skin once daily. Use of topical corticosteroids in children or on the face should be limited to the least amount compatible with an effective therapeutic regimen and duration of treatment should be no more than 5 days.

**CONTRAINDICATION:** Contraindicated in facial rosacea, acne vulgaris, skin atrophy, perioral dermatitis, perianal and genital pruritis, napkin eruptions, bacterial (e.g. impetigo, pyoderma), viral (e.g. herpes simplex, herpes zoster and chickenpox verrucae vulgares, condylomata acuminata, molluscum contagiosum), parasitical and fungal (e.g. candida or dermatophyte) infections, varicella, tuberculosis, syphilis or post-vaccine reactions, on wounds or on skin which is ulcerated, in patients who are sensitive to mometasone furoate or to other corticosteroids or to any of the ingredients in this medicine.

**WARNINGS & PRECAUTIONS:** Use with cautions or stop the treatment in condition like irritation or sensitisation develops and infection develops. Caution required for manifestations of Cushing's syndrome, hyperglycemia, glucosuria and systemic toxicity in pediatric patients due to their larger skin surface to body mass ratios and hypersensitivity to mometasone or to any of the excipients. If used on the face, courses should be limited to 5 days and occlusion should not be used. If used in psoriasis careful patient supervision is important. Avoid sudden discontinuation of treatment. Dermanex topical preparations are not for ophthalmic use, including the eyelids.

**ADVERSE REACTIONS:** Infection, furuncle, folliculitis, paraesthesia, burning sensation, dermatitis contact, skin hypopigmentation, hypertrichosis, skin striae, dermatitis acneiform, skin atrophy, pruritus, application site pain and reactions. Local adverse reactions: skin dryness, irritation, dermatitis, perioral dermatitis, maceration of the skin, miliaria and telangiectasiae. Paediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary-adrenal axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Chronic corticosteroids therapy may interfere with the growth and development of children.

**MARKETED BY:**



**TORRENT PHARMACEUTICALS LTD.**

Torrent House, Off Ashram Road,

Ahmedabad-380 009, INDIA

IN/DERMANEX CREAM 0.1%/FEB 2015/01/AbPI

(Additional information is available on request)